{"entity":{"id":"nct05943795","kind":"trial","name":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of SI-B001 and docetaxel in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active but no longer recruiting.","summary":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma is a phase 3, randomised interventional study registered as NCT05943795 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 589 participants, started 2023-07-14 and due to reach its primary completion in 2026-07. Interventions recorded: SI-B001; Docetaxel. Conditions listed: Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung. Primary outcome: Overall survival (OS); Progression-free survival (PFS). Lung eligibility wording from the registry: \"Patients with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05943795","url":"https://clinicaltrials.gov/study/NCT05943795"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-squamous-cell-carcinoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["si-b001","docetaxel"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05943795","phase":"3","setting":"A Phase III Clinical Study of SI-B001 Combined With Docetaxel Second-line Therapy in Patients With Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Without Actionable Genomic Alterations Who Failed Only First-line Treatment With PD-1/PD-L1 Monoclonal Antibody Plus Platinum-Based Chemotherapy","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":589,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05943795/","neighbours":{"cancer":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}